Dr. Lesley Russell Joins the Endocyte Board of Directors
WEST LAFAYETTE, Ind., Jan. 8, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc.
(Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule
drug conjugates (SMDCs) and companion imaging diagnostics for personalized
therapy in cancer and other serious diseases, today announced Lesley Russell,
M.B.Ch.B., has joined the Endocyte board of directors.
Dr. Russell served as senior vice president and head of research and
development for global branded products at Teva Pharmaceuticals until June
2012. Prior to this position she was executive vice president and chief
medical officer at Cephalon. Dr. Russell joined Cephalon in 2000 and held
various positions of increasing responsibility, including head of clinical
research and medical affairs, prior to becoming Cephalon's chief medical
officer in September 2006. During her tenure at Cephalon, Dr. Russell filed
multiple new drug applications (NDAs) to the FDA and marketing authorization
applications (MAAs) to the Committee for Medicinal Products for Human Use
(CHMP). Before joining Cephalon, Dr. Russell held positions of increasing
responsibility at Amgen U.K., Lilly Industries, U.K., and U.S. Bioscience, now
acquired by MedImmune Oncology.
"Dr. Russell's experience in advancing products through late-stage clinical
development will be important to Endocyte as we continue to build our
portfolio of SMDCs to develop novel cancer and inflammatory drugs in areas of
great medical need," commented Ron Ellis, president and CEO of Endocyte. "In
addition, Dr. Russell has been successful in navigating the new drug approval
process at the FDA, which will be important as our drugs approach the late
stages of clinical development. We are pleased to welcome her to our board."
Before joining the pharmaceutical industry, Dr. Russell was trained in
hematology and oncology at Royal Infirmary of Edinburgh and at Royal Hospital
for Sick Children in Edinburgh, Scotland, and was a research fellow at
University of Edinburgh. Dr. Russell received a M.B.Ch.B. degree from the
University of Edinburgh, Scotland. She is a member of the Royal College of
Physicians, U.K., and is registered with the General Medical Council, U.K. She
currently serves as a member of the board of directors of AMAG Pharma, a
company traded on NASDAQ.
Endocyte is a biopharmaceutical company developing targeted therapies for the
treatment of cancer and inflammatory diseases. Endocyte uses its proprietary
technology to create novel SMDCs and companion imaging diagnostics for
personalized targeted therapies. The company's SMDCs actively target receptors
that are over-expressed on diseased cells, relative to healthy cells. This
targeted approach is designed to enable the treatment of patients with highly
active drugs at greater doses, delivered more frequently, and over longer
periods of time than would be possible with the untargeted drug alone.The
companion imaging diagnostics are designed to identify patients whose disease
over-expresses the target of the therapy and who are therefore more likely to
benefit from treatment.
For additional information, please visit Endocyte's website at
CONTACT: Paul Cox, Stern Investor Relations, Inc.,
(212) 362-1200, email@example.com
Martina Schwarzkopf, Ph.D., Russo Partners,
(212) 845-4292, firstname.lastname@example.org
Tony Russo, Ph.D., Russo Partners,
(212) 845-4251, email@example.com
Press spacebar to pause and continue. Press esc to stop.